Evidence map›Paper›PMID 33293839›Full record

ArticleClinicoEconomics and outcomes research : CEOR2020

Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation.

Lucrezia Ferrario, Fabrizio Schettini, Elisabetta Garagiola, Adriana Cecchi, Lucia Lugoboni, Paolo Serra, Emanuele Porazzi, Emanuela Foglia

Abstract read
In one paragraph

Article in ClinicoEconomics and outcomes research : CEOR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lucrezia FerrarioCarlo Cattaneo - LIUC University and LIUC Business School, Castellanza, Italy.ORCID 0000-0002-8561-898X
Fabrizio SchettiniCarlo Cattaneo - LIUC University and LIUC Business School, Castellanza, Italy.
Elisabetta GaragiolaCarlo Cattaneo - LIUC University and LIUC Business School, Castellanza, Italy.
Adriana CecchiARCS - Azienda Regionale di Coordinamento per la Salute, Udine, Italy.
Lucia LugoboniBee Care, Lugano, Switzerland.
Paolo SerraBrotzu Hospital, Cagliari, Italy.
Emanuele PorazziCarlo Cattaneo - LIUC University and LIUC Business School, Castellanza, Italy.
Emanuela FogliaCarlo Cattaneo - LIUC University and LIUC Business School, Castellanza, Italy.ORCID 0000-0003-1381-9069

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the incremental benefits concerning the implementation of closed-system medical devices for the preparation and administration of chemotherapy agents (integrated or not with traceable workflow), within an Italian clinical practice, in which the use of such technologies is not standardized. METHODOLOGY: Four Scenarios, implying different levels of technologies introduction, were analyzed, based on the presence and/or absence of closed systems and traceable workflow, in the preparation and in the administration phase. A literature review was conducted, in order to retrieve efficacy and safety measures. Economic and organizational benefits, assuming a hospitals perspective, were assessed by means of health-economics tools, considering 27,660 (±695.86) drugs on average prepared, on an annual basis, by 12 hospitals involved. The typology of medical devices and other devices/equipment used, the human resources involved, and the time spent for the preparation and administration phases were collected.

resultsLiterature stated that the introduction of advanced technologies (CSTDs in the preparation phase, closed-system in the administration phase, both integrated by a traceable workflow) could: i) decrease surface contamination (12.24% vs 26.39%,

conclusionThe implementation of closed systems, integrated with a traceable workflow grounding on gravimetric control, may be considered a valid technological alternative within the investigated setting. The marginal incremental costs could be absorbed already in the first year after their introduction, in particular, because of the potential time saving in using closed systems in both the preparation and administration phases, demonstrating the sustainability and feasibility of such advanced technologies.

Indexed as

chemotherapy agentsclosed-system medical deviceeconomic evaluationHTAorganisational benefitssafety

Identifiers

PMID33293839
PMCPMC7718866

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.